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AbsTRACT
Objective The functional role of interleukin-22 (IL22) 
in chronic inflammation is controversial, and mechanistic 
insights into how it regulates target tissue are lacking. 
In this study, we evaluated the functional role of IL22 in 
chronic colitis and probed mechanisms of IL22- mediated 
regulation of colonic epithelial cells.
Design To investigate the functional role of IL22 in 
chronic colitis and how it regulates colonic epithelial 
cells, we employed a three- dimentional mini- gut 
epithelial organoid system, in vivo disease models and 
transcriptomic datasets in human IBD.
Results As well as inducing transcriptional modules 
implicated in antimicrobial responses, IL22 also 
coordinated an endoplasmic reticulum (ER) stress 
response transcriptional programme in colonic epithelial 
cells. In the colon of patients with active colonic Crohn’s 
disease (CD), there was enrichment of IL22- responsive 
transcriptional modules and ER stress response modules. 
Strikingly, in an IL22- dependent model of chronic colitis, 
targeting IL22 alleviated colonic epithelial ER stress and 
attenuated colitis. Pharmacological modulation of the 
ER stress response similarly impacted the severity of 
colitis. In patients with colonic CD, antibody blockade of 
IL12p40, which simultaneously blocks IL12 and IL23, the 
key upstream regulator of IL22 production, alleviated the 
colonic epithelial ER stress response.
Conclusions Our data challenge perceptions of IL22 as 
a predominantly beneficial cytokine in IBD and provide 
novel insights into the molecular mechanisms of IL22- 
mediated pathogenicity in chronic colitis. Targeting IL22- 
regulated pathways and alleviating colonic epithelial ER 
stress may represent promising therapeutic strategies in 
patients with colitis.
Trial registration number NCT02749630.
InTRODuCTIOn
Inflammatory bowel disease (IBD), comprising 
ulcerative colitis (UC) and Crohn’s disease (CD), 
is a paradigmatic immune- mediated inflammatory 
disease (IMID). IBD is characterised by excessive 
accumulation of immune cells in the gut and induc-
tion of complex inflammatory networks.1 Similar 
to the situation for other IMIDs, the precise cause 
of IBD remains elusive, and the role of individual 
cytokines and immune pathways can be difficult 
to deconvolute. Simultaneous mobilisation of anti- 
inflammatory and tissue restitution factors adds yet 
further complexity to the picture. Interleukin-22 
(IL22) is a highly controversial cytokine. Currently, 
the prevailing view is that IL22 promotes gastroin-
testinal health by supporting LGR5+ epithelial stem 
cell regeneration/proliferation.2 This protective 
role is most obviously observed in animal models 
of intestinal epithelial injury resulting from acute, 
self- limiting insults. In acute colonic infections, 
such as Citrobacter rodentium, where rapid repair 
of colonic epithelial cells is required, IL22 plays a 
protective role.3 4 Likewise, IL22 facilitates epithe-
lial restitution after induction of acute injury after 
short- term exposure to the detergent DSS, which 
results in abrupt tissue injury that rapidly resolves 
shortly after removal of the chemical insult.5 6 
Administration of the chemotherapy agent metho-
trexate also induces a self- resolving mucositis char-
acterised by acute small intestinal epithelial damage, 
in which IL22 plays an important restorative role.7 
Importantly, in these examples, the primary insult is 
epithelial disruption, where it seems IL22 performs 
an important restorative role, driving epithelial 
proliferation and restitution. Together these data 
have been interpreted as indicating that IL22 could 
be clinically useful to promote epithelial repair in 
IBD and has culminated in a clinical trial evaluating 
the role of recombinant IL22 therapy in patients 
with active IBD.
However, an alternative view of IL22 is emerging 
to challenge this dogma, especially in the context 
of chronic inflammation, rather than acute, self- 
limiting mucosal injury. IBD is not an acute inflam-
matory disease, and in the majority of patients nor is 
it likely to be caused by a primary epithelial defect. 
IBD has been a major beneficiary of the genome 
wide association studies (GWAS) revolution, and 
while disease risk conferring polymorphisms at 
epithelial loci are recognised, the majority of them 
localise at immune genes. Some preclinical models 
of IBD indicate that IL22 may actually contribute 
to disease.8–11 Moreover, blockade of IL23, the key 
upstream cytokine responsible for triggering IL22 
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production, looks to be very promising in early phase clinical 
studies in IBD.12 13 Indeed, high serum levels of IL22 predict 
response to anti- IL23 treatment.13 Consequently, additional 
insights into the role of IL22 in chronic colitis are urgently 
needed to inform therapeutic strategy, especially now that clin-
ical trials evaluating the efficacy of recombinant IL22 adminis-
tration to patients with active IBD are starting to be pursued.
Accordingly, there is a pressing need for new insights into 
the role of IL22 in chronic inflammation. Importantly, the IL22 
receptor is exclusively expressed by epithelial cells in the gut, and 
in IBD, there is an especially compelling case to probe interac-
tions between IL22 and the colonic epithelium, since the colon is 
exclusively affected in UC and affects most patients with CD.1 In 
this study, we have exploited colonic epithelial organoids, in vivo 
disease models and tissue transcriptomics in a large datasets of CD 
patients with active colitis to probe IL22- colonic epithelial inter-
actions and provide mechanistic insights into this critical dialogue.
MeThODs
Experimental methods, including in vivo treatment, cell isola-
tion protocols, organoid cultures, gene expression profiling, 
immunoblotting, immunohistochemistry, fluorescence activated 
cell sorting (FACs), details of the UNITI trial programme and 
statistical methods are shown in online supplementary methods.
ResulTs
Il22 regulates an endoplasmic reticulum (eR) stress response 
transcriptional module in colonic epithelial cells, which is 
augmented by Il17A
To probe interactions between IL22 and the colonic epithelium, 
we exploited a colonic epithelial organoid system. Colonic crypts 
were harvested from mouse colons and cultured to form three- 
dimensional organ buds that retained phenotypic and functional 
characteristics of intact primary colonic epithelial cells14 (online 
supplementary figure 1). Colonic epithelial organoids (‘colo-
noids’) were treated with recombinant IL22 and transcriptional 
responses mapped by gene expression microarray analysis. In 
this system, IL22 modulated expression of 859 genes (online 
supplementary table 1), including genes encoding antimicrobial 
peptides, such as recognised IL22- responsive transcripts, Reg3b 
and Reg3g, but also other antimicrobial molecules, including the 
calprotectin subunits S100a8/S100a9, lipocalin-2 (Lcn2) and 
lactoferrin (Ltf). IL22 had no impact on the expression of α or 
β-defensin family antimicrobial peptides. IL22 induced signif-
icant upregulation of transcripts involved in microbial sensing 
(Tlr4, Myd88, Tnfaip3) and epithelial barrier function, including 
claudin family genes encoding important colonic epithelial tight 
junction proteins (figure 1A). Recently, IL22 has been reported 
to induce ER stress in small intestinal epithelial cells in vivo 
and in vitro, which is associated with heightened susceptibility 
to experimental small intestinal inflammation, especially in the 
context of Atg16l1 deficiency.11 Infective, metabolic, toxic or 
inflammatory cellular insults can overwhelm protein synthesis in 
the ER, resulting in accumulation of potentially toxic misfolded 
proteins and ER stress.15 The unfolded protein response (UPR) 
is a highly conserved cellular process that functions to miti-
gate against the harmful effects of protein misfolding. In our 
colonoid system, IL22 also significantly upregulated key tran-
scripts responsible for controlling the UPR (figure 1A and online 
supplementary table 1).
To further understand the transcriptional architecture of a 
pathological ER stress response in the colonic epithelial compart-
ment, we treated colonoids with tunicamycin, a powerful chemical 
inducer of a pathological ER stress response.16 Tunicamycin signifi-
cantly modulated the expression of 217 genes in colonoids (online 
supplementary table 2), and enrichment analysis for functional 
annotation groups demonstrated significant association with 
cellular processes associated with ER stress, including ‘response 
to unfolded protein’ and ‘response to ER stress’ (online supple-
mentary figure 2). Gene Set Enrichment Analysis17 confirmed 
significant enrichment of the colonic epithelial compartment- 
specific ER stress response transcriptional module in IL22 treated 
colonoids (figure 1B). These data were corroborated by real time 
PCR, confirming that IL22 induced transcription of core ER stress 
response transcripts in a time and dose dependent manner (online 
supplementary figure 3). We validated these findings in an indepen-
dent, published dataset of genome- wide transcriptional changes in 
colonic epithelial cells generated using a different gene expression 
platform (RNA sequencing).18 In agreement with our data, IL22 
induced an ER stress response transcriptional programme in WT 
colonoids, but not in Il22ra1−/− colonoids, additionally confirming 
that this pathway is dependent on signalling through the conven-
tional IL22 receptor (figure 1C). Comparable findings were 
observed at pathway level, with significant enrichment of tran-
scripts annotated to Gene Ontology (GO) terms, such as ‘response 
to ER stress’ and ‘ER stress overload response’ (figure 1D).
We also observed that IL22 synergistically augmented 
tunicamycin- induced transcription of core ER stress genes in our 
microarray analysis (figure 1E and online supplementary table 3), 
which was corroborated by real time PCR (online supplementary 
figure 4), indicating that IL22 might also potentiate the ER stress 
response driven by other mediators. We reasoned that this might 
be especially important in chronic inflammation, where other 
proinflammatory mediators are present in the local tissue envi-
ronment. IL22 is often coproduced with IL17A19 20; therefore, 
we considered the possibility that IL22 might synergise with 
IL17A to drive the ER stress response. By itself IL17A was only 
a weak inducer of ER stress- associated transcripts; however, in 
combination with IL22, there was stronger induction of UPR 
transcripts (figure 1F). Additionally, we evaluated whether IL22 
and IL17A induced an ER stress response at protein level in 
colonoids. Western blotting for GRP78 in cytokine- treated colo-
noids demonstrated increased immunoreactivity for GRP78 only 
in colonoids treated with both IL17A and IL22 in combination 
(figure 1G,H).
Next, we considered whether IL17A/IL22- induced ER stress 
was directed at the epithelial stem cell niche or non- stem epithe-
lial cells. To address this question, colonoids were generated 
from Lgr5- GFP reporter mice, permitting distinction between 
Lgr5+ colonic epithelial stem cells and the Lgr5− non- stem cell 
epithelial compartment (online supplementary figure 5A,B). 
Following exposure to IL17A and IL22, colonoids were disso-
ciated into single cell suspensions and FACS purified into 
GFP+ stem cells and GFP− epithelial populations. IL22/IL17A 
significantly induced increased expression of sXbp1 and Grp78; 
although the magnitude of induction was greater in the Lgr5+ 
epithelial stem cell compartment, there was also induction in the 
Lgr5− non- stem cell epithelial compartment (online supplemen-
tary figure 5C). These results indicate that the ER stress response 
was directed at both stem cell and non- stem cell epithelial cells.
Il22 and Il17A promote eR stress and intestinal epithelial 
apoptosis
Although the UPR is mobilised to restore cellular homeostasis, 
unresolved ER stress results in a pathological UPR response, 
proinflammatory signalling and induction of proapoptotic path-
ways.15 21 22 In addition to upregulation of ER stress response 
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Figure 1 IL22 induces an ER stress/unfolded protein response transcriptional module in colonic epithelial cells. (A) Heat map demonstrating 
pathway specific transcript expression in murine colonoids treated with (+IL22, n=3) or without (control, n=3) recombinant IL22. Mouse gene 2.0 
ST array platform (affymetrix). (B) GSEA evaluating enrichment of ER stress response transcriptional module in IL22 treated colonoids. A core set of 
colonic epithelial- specific ER stress genes was defined by analysing significantly differentially expressed (p<0.05 and absolute value of the log2 fold 
change >±2) transcripts in colonoids treated with tunicamycin (n=3) or medium alone (n=3). (C) Expression of ER stress response transcripts in IL22 
treated WT and Il22ra1−/− colonoids (RNA- seq dataset ERR247358- ERR247389, Pham et al, 2014).18 (D) Enrichment analysis for ER stress- related 
functional annotation groups (GO biological processes) in IL22- treated colonoids from dataset ERR247358- ERR247389. (E) Microarray analysis of core 
ER stress response transcripts in colonoids treated with tunicamycin (n=3), tunicamycin+IL22 (n=3) or untreated (control, n=3). (F) Real- time PCR 
quantification of ER stress transcripts in colonoids treated with IL22 (n=11), IL17A (n=6) and IL22+IL17A (n=6) and unexposed controls. *P<0.01. 
(G) Immunoblot and densitometry quantification (H) detecting GRP78 protein expression in colonoids treated with different cytokines. *P<0.026, one 
tailed t test. ER, endoplasmic reticulum; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; IL22, interleukin-22.
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transcripts, we also observed upregulation of transcripts that 
impact the inflammatory tone of the colonic epithelium, 
including susceptibility to apoptosis. IL22 induced the expression 
of Tnf (a proinflammatory and proapoptotic cytokine), induc-
ible nitric oxide synthetase (Nos2, which has been implicated 
as a trigger for epithelial inflammation, carcinogenesis and ER 
stress)23 24 and the proinflammatory/proapoptotic intracellular 
molecule Sting (Tmem173, a potent proinflammatory mediator 
linking intracellular pattern recognition receptors to activation 
of innate immunity)25 (figure 2A and online supplementary table 
1). Indeed, Sting has previously been linked to IL22- induced 
apoptosis.8–11 There was also induction of caspase 12, a member 
of the caspase family that is itself anchored in the ER and is 
responsible for regulating ER stress- associated apoptosis15 21 22 
(figure 2A). These findings were replicated in the independent 
transcriptomic dataset from Pham et al18 (figure 2A).
Pathway level analyses also indicated that IL22 might prime for 
apoptosis in colonic organoids. Classification of gene function of 
all IL22- regulated transcripts (315 annotated genes with ≥1.5- 
fold increased expression), using protein annotation through 
evolutionary relationship (PANTHER) analysis26 demonstrated 
significant enrichment of expected pathways, such as ‘inter-
leukin signalling’, ‘Inflammation mediated by chemokine and 
cytokine signalling pathway’ and ‘Toll- like receptor signalling’ 
(figure 2B). However, the single most enriched pathway was 
‘apoptosis’. These findings were replicated in the Pham dataset 
(RNA sequencing),18 and in agreement with our data, pathway 
mapping of IL22 colonoids using the Kyoto Encyclopedia of 
Genes and Genomes27 system identified activation of compa-
rable pathways. As expected, there was significant enrichment 
of pathways involved in ‘bacterial invasion of epithelial cells’, 
‘tight junctions’, ‘cytokine- cytokine receptor interactions’ and 
‘colorectal cancer’; however, we also observed a highly signif-
icant association with ‘apoptosis’ (p<10−7) (online supplemen-
tary figure 6).
Importantly, in our microarray analysis of IL22- induced gene 
expression changes, we observed upregulation and downregula-
tion of different apoptotic genes; therefore, to further investigate 
the observed differential gene expression patterns on the activity 
of the apoptotic process computationally, we used the Qiagen 
Ingenuity Pathway Analysis. The tool considers the concordance 
between the directionality of the gene expression changes from 
an experiment and those known to activate (positive z- score) or 
inhibit (negative z- score) a given pathway. Predictions for whole 
pathways are made by assessing statistically such level of agree-
ment. We found that apoptosis pathways were significantly, yet 
moderately, activated in IL22- treated mouse colonoids for apop-
tosis pathways, including ‘apoptosis’ (activation z- score=0.511, 
p=3.17−15) and ‘epithelial apoptosis’ (activation z- score=0.695, 
p=3.28−14).
To determine whether IL22 might impact epithelial cell 
viability, we performed an MTT (reduction of 3-(4,5- dimethy
lthiazol-2- yl)-2,5- diphenyltetrazonium bromide) viability assay. 
Tunicamyin induces ER stress, apoptosis and barrier disruption 
in intestinal epithelial cells,16 and as expected, there was signifi-
cant loss of epithelial cell viability in colonoids treated with tuni-
camycin (figure 2C). Although IL17A and IL22 by themselves 
did not significantly impact cell viability, there was significant 
loss of cell viability in colonoids treated with a combination of 
IL22 and IL17A, although these effects were less pronounced 
than observed with tunicamycin (figure 2C). To determine 
whether IL22 and IL17A could impact on intestinal epithelial 
apoptosis in an in vivo setting, we assessed the impact of cyto-
kine administration in a model of intestinal epithelial apoptosis. 
A single dose of tumour necrosis factor-α (TNFα) induces 
rapid epithelial cell apoptosis, predominantly at the villus tips, 
accompanied by villus shortening, fluid exudation into the gut 
lumen and diarrhoea.28 29 TNFα delivery induced enterocyte 
cell death and shedding, predominantly in the villus tips of the 
intestine (figure 2D). This response was detectable from around 
90 min post- TNFα administration and was most pronounced 
at 120 min, with numerous shed cells visible in the lumen, and 
high numbers of TUNEL+ and caspase-3+ epithelial cells on the 
villi, which started to taper by 150 min (figure 2D–F). Pretreat-
ment with IL22, resulted in earlier detection of intense shed-
ding, from 60 min, while pretreatment with combined IL22/
IL17A accelerated the response even further, with increased cell 
shedding and apoptosis observed just 40 min post- TNFα delivery 
(figure 2D–F). Quantification of caspase-3+ cells showed that 
the apoptotic response to TNFα was significantly increased by 
both IL22 and IL22/IL17 pretreatments (figure 2D–F). Taken 
together these data indicate that IL22, particularly in combi-
nation with IL17A, promotes colonic epithelial apoptosis. This 
property may be especially pronounced in chronic inflamma-
tion, when other proapoptotic factors are abundant (eg, TNFα), 
or indeed following unresolved ER stress response, which also 
culminates in apoptosis.
Il22 is a functionally important driver of colonic eR stress in 
chronic colitis
Next, we asked whether the IL22/ER stress axis was function-
ally important in chronic colitis. To address this question, we 
exploited the TRUC model of IBD, which mirrors some aspects 
of chronic colitis in human IBD. TRUC mice develop chronic 
microbiota- dependent colitis, mediated by pathogenic group 3 
innate lymphoid cells, and disease is alleviated following admin-
istration of anti- TNFα or anti- IL23p19 mAbs.14 19 20 Profiling 
the colonic transcriptome of TRUC mice demonstrated signifi-
cant enrichment of IL22- responsive transcripts in the colon of 
TRUC mice. Indeed, the majority of the most highly induced 
transcripts in IL22 treated colonoids were additionally upreg-
ulated in the colon of TRUC mice (figure 3A). Consistent with 
the enrichment of ER stress response transcripts observed in 
the colon of TRUC mice, we also observed increased immuno-
reactivity of IRE1α, an endoribonuclease responsible for Xbp1 
splicing, in the colonic epithelium of TRUC mice (figure 3B). 
As a positive control, we also observed increased IRE1α immu-
noreactivity in the colonic epithelium of Villin- cre × Atg16l1fl/
fl mice, where impaired autophagy results in a pathological 
ER stress response (figure 3B). Western blotting confirmed 
increased expression of Grp78 protein in the colon of TRUC 
mice in comparison with Rag2−/− mice (figure 3C and online 
supplementary figure 7).
Next, we investigated the functional impact of increased 
epithelial ER stress in TRUC mice by pharmacological alleviation 
of ER stress by administering 4- phenylbutryic acid (4- PBA), an 
inhibitor of ER stress. 4- PBA administration reduced ER stress 
and significantly attenuated colitis in TRUC mice (figure 3D 
and online supplementary figure 8), consistent with an exag-
gerated ER stress response contributing to colitis severity. To 
further probe the functional role of the IL22 in driving epithelial 
ER stress in vivo, we employed genetic ablation and antibody 
blockade experiments. In comparison with TRUC mice, germ 
line genetic deletion (TRUC Il22−/−) or neutralisation (anti- IL22 
mAb) significantly reduced ER stress and completely attenuated 
colitis (figure 3E–H). Taken together these data indicate that 
IL22 plays a functionally important role in chronic colitis in 
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Figure 2 IL22 and IL17A promote ER stress and intestinal epithelial apoptosis. (A) Transcript expression in IL22- treated colonoids from our dataseta 
and Pham et al ERR247358- ERR247389b. (B) Panther analysis of pathways activated in IL22- treated colonoids. (C) MTT assay demonstrating colonic 
epithelial cell viability after treatment with IL22, IL22+IL17A, or tunicamycin, versus untreated colonoids. *P<0.02, **P<0.0001. (D) In vivo model 
of intestinal epithelial apoptosis showing representative immunohistochemistry (caspase 3 immunoreactivity) and statistical analyses (E and F) of 
intestinal sections harvested at different time points following pretreatment with either IL22, IL22+IL17A, or PBS, prior to administration of TNFα. 
*P<0.005. IL22, interleukin-22.
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Figure 3 IL22/ER stress axis is functionally important in chronic colitis. (A) Volcano plot (fold change vs p value) showing gene expression in the 
colon of Rag2−/− (n=3) and TRUC (n=3) mice, microarray analysis (MouseWG-6 v2.0 expression BeadChip, Illumina). Transcripts annotated in red are 
among the top 20 most highly upregulated genes in IL22- treated colonoids. (B) Representative immunohistochemistry (IRE1α immunoreactivity) in 
distal colon of villin- cre Atg16l1fl/fl mice and TRUC mice. (C) Western blot of distal colon segments from TRUC and Rag2−/− mice probed with anti- 
GRP78. Corresponding densitometry plots are shown in online supplementary figure 7. (D) Representative histology (H&E) and histology scores of the 
distal colon of TRUC mice administered 4- PBA in drinking water (n=8) or water alone (n=8). P<0.025. (E) Colon micrograph (H&E stain), and colitis 
score of distal colon of TRUC mice treated with anti- IL22 mAb (n=6) or control antibody (n=10). P<0.001. (F) Colitis score of distal colon of TRUC 
(n=16) and TRUC Il22−/− (n=10) mice. P<0.0001. (G) Western blot of distal colon segments from TRUC and TRUC Il22−/− mice probed with anti- GRP78. 
Corresponding densitometry plots are shown in online supplementary figure 7. (H) Real- time PCR quantifying ER stress transcripts in the distal colon 
of TRUC mice (n=9), TRUC Il22−/− mice (n=5) and TRUC mice treated with anti- IL22 (n=6). *P<0.05, **P<0.02, ***P<0.001. 4- PBA, 4- phenylbutryic 
acid; IL22, interleukin-22.
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Figure 4 Local induction of ER stress reinstates colitis in TRUC Il22−/− mice. (A) Histological appearance (H&E stain) and colitis score of the distal 
colon, and (B) colon mass of TRUC mice treated with intrarectal tunicamycin (n=8) or vehicle control (n=9). *P<0.01. Bar charts depict mean and SEM 
in graphs showing dots, each dot represents an individual mouse.
TRUC mice and that targeting IL22, or pathological ER stress in 
the epithelium, alleviates colitis.
local induction of eR stress re-instates colitis in otherwise 
healthy TRuC Il22−/− mice
Since TRUC Il22−/− mice do not develop colonic epithelial ER 
stress and are protected from colitis, we hypothesised that direct 
induction of colonic epithelial ER stress, even in the absence of 
IL22, should be sufficient to reinstate disease. To address this 
question, we administered tunicamycin intrarectally to healthy 
TRUC Il22−/− mice. Strikingly, in contrast to vehicle- treated 
mice, tunicamycin induced increased colonic mass and histolog-
ical features of colitis in TRUC Il22−/− mice (figure 4A,B).
Il22-responsive transcripts are increased in the colon of 
patients with IbD and correlate with key biomarkers and the 
severity of mucosal injury
Next, we sought to determine whether these observations might 
be relevant in human colitis. We investigated the expression 
of IL22- responsive transcriptional networks and the ER stress 
response in colonic tissue from CD patients with active colitis. 
To address this question, we interrogated transcriptomic, sero-
logical and clinical data from a large cohort of patients with 
active colonic CD from the UNITI study, a large phase III trial 
programme evaluating the efficacy of ustekinumab, a human 
IgG1κ mAb targeting the p40 subunit common to both IL12 and 
IL23.30 Colonic biopsies were sampled at baseline (ie, before 
administration of the study drug) and longitudinally following 
initiation of drug. In both UNITI-1 and UNITI-2 cohorts, serum 
IL22 concentration was significantly increased in comparison 
with healthy control subjects (figure 5A). We evaluated tissue 
transcriptomics in rectal biopsies of patients with CD from the 
UNITI cohort at baseline in comparison with healthy control 
subjects, who were not part of the UNITI trial programme but 
whose biopsy gene expression data were generated and analysed 
in parallel. Using the Human Genome U133 Plus 2.0 Array plat-
form, the probe sets for cytokines, including IL22, IL17A and 
TNF, generally hybridised at low intensity, such that compar-
ison of cytokine transcripts between the groups was difficult to 
determine (data not shown). However, we reasoned that if IL22 
was biologically active in diseased colonic tissue of patients with 
colitis, then core IL22- responsive transcripts would be enriched 
in rectal biopsies of CD patients with active colitis in compar-
ison with non- inflammatory control subjects. We defined a core 
IL22- responsive transcriptional programme by identifying the 
human homologues of the 20 most highly upregulated tran-
scripts in IL22- treated colonoids. Strikingly, Gene Set Varia-
tion Analysis (GSVA)31 demonstrated significant enrichment of 
the IL22- responsive transcriptional module (figure 5B). These 
findings were replicated in colonic biopsies sampled from an 
independent cohort of IBD patients with colonic CD and active 
UC (GSE16879, online supplementary figure 9).32 As well as 
demonstrating significantly higher expression levels of IL22 
responsive transcripts in patients with active colonic IBD, unsu-
pervised hierarchical clustering could fully differentiate CD and 
UC patients from controls (online supplementary figure 10). 
In the UNITI cohort extensive phenotypic data were available, 
including disease activity scoring, endoscopic severity scoring 
and measurement of inflammatory biomarkers. Crucially, 
enrichment scores for IL22- responsive transcripts correlated 
with biomarkers of disease activity and severity, including faecal 
lactoferrin and calprotectin concentrations (figure 5C,D). More-
over, the IL22 enrichment score in rectal biopsies significantly 
correlated with the severity of mucosal injury scored during 
endoscopy, calculated using the Simple Endoscopic Score – 
Crohn’s Disease (SES- CD), which quantifies endoscopically 
assessed severity of inflammation and is arguably the most 
important objective marker of CD severity/activity (figure 5D). 
Principal component analysis demonstrated that IL22 responsive 
transcripts could discriminate between the presence or absence 
of epithelial ulceration in the rectum identified during endos-
copy (figure 5E). To further explore the correlation between 
IL22 responsive transcripts and severity of mucosal injury, we 
adopted a machine learning approach to evaluate the ability of 
IL22- responsive transcripts to predict endoscopic activity (SES- 
CD). Elastic Net regression33 was conducted to select genes from 
the IL22 signature to predict endoscopic disease severity. The 
rectum baseline gene expression data were used for training and 
those from rectum at week 8 and splenic flexure and terminal 
ileum at baseline and week 8 served as testing datasets. A model 
derived from the UNITI-1 discovery data set was predictive of 
the baseline SES- CD score with R2 of 0.82 (figure 5G–H). We 
validated the performance of this model in the testing datasets 
from the same study (r2 range between 0.35 and 0.64), with the 
best performance in the week 8 rectum (r2=0.64, figure 5H), 
confirming that IL22 responsive transcripts can predict severity 
of SES- CD in colonic CD. Finally, we asked whether the expres-
sion of the IL22- responsive transcriptional module in biopsies 
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Figure 5 Increased expression of IL22 and IL22- regulated transcriptional modules in active colitis. (A) Serum IL22 concentration in healthy control 
(HC; n=29) and patients with CD from UNITI1 (n=191) and UNITI2 (n=205) trial programmes. *P<0.0005, **p<0.0001). (B) IL22 responsive transcript 
GSVA enrichment scores of the 20 mostly highly upregulated IL22 responsive transcripts in patients with CD (n=162) from the UNITI trial programme 
(at baseline prior to randomisation to placebo or ustekinumab) or HC subjects (n=23). Each dot represents an individual patient. Line depicts median. 
Gene expression data for the UNITI cohort were quantified using the Affymetrix Hg U133 PM array. *P<0.0003. (C) GSVA showing IL22 responsive 
transcript enrichment scores in colonic biopsies from patients with active (Mayo endoscopy subscore 2–3) or quiescent (Mayo endoscopy subscore 
0–1) UC, CD or HCs (gene expression microarray datasets GSE50971 and GSE16879). (C–E) Correlation between IL22 enrichment score (GSVA) in 
rectal biopsies of patients with CD, with faecal calprotectin (C), faecal lactoferrin (D) and (E) regional SES- CD (ie, endoscopic severity of mucosal 
disease at same site mucosal biopsy was sampled from). Displayed is baseline rectum gene expression from UNITI-1 subpopulation with colon 
involvement. Faecal calprotectin and lactoferrin were log 2 transformed data. (F) PCA of baseline rectum gene expression of IL22 responsive genes in 
UNITI-1 segregates CD patients with and without baseline ulceration. (G) A multivariant model using IL22- responsive transcripts to predict endoscopic 
activity by SES- CD in UNITI cohort, with correlation of predicted and actual SES- CD score in the training set using baseline rectal biopsies in UNITI-1. 
(H) Coefficients of determination of the training and testing datasets in UNITI-1 and genes used in the predictive model. *Predicted SES- CD at left 
colon; ˆGenes sorted by selection order. bL, baseline; CD, Crohn’s disease; GSVA, Gene Set Variation Analysis; IL22, interleukin-22; R2, coefficient of 
determination; SES- CD, Simple Endoscopic Score – Crohn’s Disease; Wk8, week 8.
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sampled at baseline, prior to institution of ustekinumab, could be 
harnessed to predict response to treatment in the UNITI cohort. 
Using PCA, the IL22 responsive signature could not differentiate 
responders and non- responders to ustekinumab in the UNITI 
cohort (online supplementary figure 11).
An epithelial cell-specific eR stress-driven transcriptional 
programme is enriched in active colitis and correlates with 
the Il22 transcriptional footprint
Next, we investigated whether the ER stress response tran-
scriptional programme might also be enriched in the colon of 
patients with active colitis. To generate a colon epithelial cell- 
specific ER stress- associated transcriptional module, we identi-
fied the genes induced by tunicamycin in murine colonoids and 
cross referenced them with their human homologues involved in 
the ER stress pathway, generating a list of 62 genes (figure 6A). 
GSVA confirmed that this colonic epithelial cell- specific, ER 
stress response transcriptional module was significantly enriched 
in the colon of patients with colonic CD in the UNITI cohort 
(figure 6B) and replicated in an independent dataset of patients 
with colonic CD and UC (figure 6C). Unsupervised hierarchical 
clustering according to expression of these 62 ER stress response 
transcripts could fully differentiate between patients with 
colonic CD and non- inflammatory control patients (figure 6D), 
and significantly correlated with key disease features, including 
faecal lactoferrin concentration (figure 6E) and endoscopic 
severity of mucosal injury (figure 6F). In keeping with a role for 
IL22 in driving an ER stress transcriptional module in human 
colitis, the magnitude of enrichment of IL22 responsive tran-
scripts in the colon across the population of patients with CD 
significantly correlated with the magnitude of enrichment of the 
ER stress transcriptional module (figure 6G).
In vivo blockade of the Il23/Il22 axis reverses eR stress in 
Crohn’s colitis
We reasoned that if there was a causal relationship between 
IL22 and ER stress in human colonic inflammation, modu-
lating the IL22 pathway might be expected to alleviate the ER 
stress transcriptional module in the colon. IL23 is the key cyto-
kine responsible for triggering IL22 production; therefore, we 
tested the hypothesis that IL23 blockade would resolve colonic 
epithelial ER stress in human colitis. To address this question, 
we investigated the colonic transcriptome in the subset of 
patients from the UNITI trial programme treated with usteki-
numab or placebo, in whom colonic biopsies had been serially 
sampled for RNA extraction at baseline, week 8 and week 44. 
Over time, in placebo- treated patients with CD, there was no 
significant change in the expression of XBP1 or GRP78 expres-
sion in the rectum. However, in patients treated with usteki-
numab, there was a significant reduction in the expression of 
these transcripts by week 44 (figure 7A). Similarly, enrichment of 
the 62- transcript epithelial cell- specific transcriptional module 
remained unchanged in the colon of placebo- treated patients 
with CD, whereas it was significantly reduced in patients treated 
with ustekinumab (figure 7B). Taken together, these data are 
consistent with the IL23/IL22 axis playing an important role 
regulating colonic epithelial ER stress in IBD patients with 
colonic involvement.
DIsCussIOn
This study provides new insights into the dialogue between IL22 
and colonic epithelial cells in the context of chronic inflamma-
tion. IL22 regulated a transcriptional programme that shaped 
the inflammatory tone of the colonic epithelium, regulating tran-
scripts including Tnf, inducible nitric oxide synthetase (Nos2) and 
pro- apoptotic factors, such as caspase 12 and Sting (Tmem173). 
Furthermore, IL22 also regulated an ER stress response module, 
which was amplified by IL17A, a cytokine it is commonly 
coproduced with.19 20 UPR induction is usually compensatory, 
to mitigate the harmful effects of misfolded proteins. However, 
persistence of triggering ER stressors, including chronic expo-
sure to environmental insults and genetic factors, may result in 
unresolved ER stress, which in turn culminates in a pathogenic 
response and induction of apoptosis. These divergent cellular 
destinies following UPR engagement could potentially explain 
the contradictory, proinflammatory and anti- inflammatory roles 
attributed to IL22. For instance, IL22 is required for epithelial 
recovery in self- limiting colonic infections or following short- 
term exposure to chemicals that are directly toxic to intestinal 
epithelial cells.2 4 6 7 18 34–36 Induction of an adaptive UPR in this 
acute setting would likely be beneficial to overcome short- lived 
protein misfolding occurring during cellular stress to facilitate 
recovery. Even limited induction of apoptosis could be bioen-
ergetically favourable in acute injury, allowing unsalvageable 
cells to be abandoned and priming the tissue for newly gener-
ated epithelial cells to replenish the barrier. Other functions of 
IL22, such as induction of epithelial stem cell proliferation to 
support epithelial repopulation would complement this activity. 
However, epithelial cell fate in response to IL22 induction of 
the UPR is likely to be very different in chronic inflammation, 
where persistent immune activation and excessive production 
of many different proinflammatory mediators occurs. Indeed, 
increased ER stress is observed in primary epithelial cells and 
colonic biopsies from patients with IBD.37–39 Crucially, sustained 
UPR activation triggers apoptosis, including an ER- specific 
apoptotic response mediated by ER anchored caspase 12.15 21 
In keeping with a detrimental impact of persistent UPR engage-
ment, chronic models of intestinal inflammation, including the 
TRUC model of IBD described in this study, blockade or genetic 
deletion of IL22 alleviates disease,8–11 consistent with a non- 
redundant proinflammatory role for IL22.
In this study, IL22 induced increased expression of caspase 12 
in colonic epithelial cells, which is recognised as a crucial step in 
the transition of a sustained UPR to induction of apoptosis.21 22 
Similarly, IL22 induced expression of the pro- apoptotic medi-
ator STING, which plays an important role in triggering type 
I interferon induction and increased small intestinal epithelial 
apoptosis.11 The pathological impact of IL22 on small intestinal 
epithelium is directly influenced by the inflammatory tone of 
the epithelium and disruption of autophagy, which promotes 
proinflammatory activity significantly amplifies pathological 
ER stress.11 The role of IL22 in the regulation of epithelial cell 
survival is complex, and it is likely that different epithelial cell 
lineages are differentially impacted by both ER stress induction 
and susceptibility to apoptosis. Although definitive identifica-
tion of which lineages are impacted was beyond the remit of the 
current study, we observed induction of an ER stress response 
in both LGR5+ epithelial cells as well as the LGR5− epithelial 
compartment. Recently published data using small intestinal 
enteroids indicates that IL22 induces proliferation of transit- 
amplifying epithelial cells but simultaneously induces apop-
tosis of LGR5+ stem cells through inhibition of Wnt and notch 
signalling.40 Future work, including single cell sequencing exper-
iments, will focus on defining the differential impact of different 
cytokines in different colonic epithelial lineages.
For the first time we show that IL22 performs a non- redundant, 
pathogenic role in the TRUC model of chronic colitis. Genetic 
587Powell N, et al. Gut 2020;69:578–590. doi:10.1136/gutjnl-2019-318483
Recent advances in basic science
Figure 6 Colonic epithelial cell- specific ER stress response transcriptional module is enriched in IBD patients with active colitis. (A) Diagrammatic 
representation of how our colonic epithelial- specific ER stress response transcriptional signature was derived. (B) ER stress response GSVA enrichment 
scores in colonic biopsies from CD patients from the UNITI trial programme (at baseline prior to randomisation to placebo or ustekinumab) or healthy 
control subjects. Each dot represents an individual patient. line depicts median. *P<0.0001 (CD vs control). (C) ER stress response GSVA enrichment 
scores in colonic biopsies from UC, CD and healthy control (HC) patients from an independent dataset (GSE16879). *p<0.0005, **p<0.0001. (D) heat 
MAP depicting transcript level changes using unsupervised hierarchical clustering of the ER stress transcriptional module in patients with colonic 
CD and healthy, non- inflammatory control subjects (GEO59071). (E) Correlation between ER stress GSVA enrichment score and faecal lactoferrin 
concentration (log2) transformed data and (F) regional SES- CD. Displayed is baseline rectum gene expression from UNITI-1 subpopulation with colonic 
involvement. (G) Correlation between IL22 GSVA enrichment score and epithelial cell- specific ER stress GSVA enrichment score. CD, Crohn’s disease; 
DEGs, differentially expressed genes; ER, endoplasmic reticulum; GO, Gene Ontology; GSVA, Gene Set Variation Analysis; IL22, interleukin-22; SES- CD, 
Simple Endoscopic Score – Crohn’s Disease.
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Figure 7 Blockade of the IL12/IL23 axis with ustekinumab alleviates colonic ER stress in CD patients with active colitis. (A) quantification of 
transcripts encoding XBP1 and GRP78 (log2 transformed expression intensity) in colonic biopsies of patients with CD in UNITI-1 randomised 
maintenance population post- treatment with maintenance placebo or maintenance ustekinumab (pooled data of ustekinumab 90 mg SC every 12 
weeks and ustekinumab 90 mg SC every 8 weeks at week 44 comparing to week 0. (B) GSVA enrichment scores of ER stress signatures in the UNITI-2 
pooled (randomised and non- randomised) maintenance population who received placebo or ustekinumab 90 mg every 8 weeks maintenance therapy 
until week 44 comparing with week 0). Gene expression data for the UNITI cohort were quantified using the Affymetrix Hg U133 PM array. CD, 
Crohn’s disease; ER, endoplasmic reticulum; IL22, interleukin-22; GSVA, Gene Set Variation Analysis.
ablation or antibody blockade of IL22 reversed the ER stress 
response and attenuated disease, although disease could be rein-
stated in TRUC Il22−/− mice by local pharmacological induc-
tion of ER stress in the colon. Pharmacological alleviation of 
ER stress attenuated TRUC disease. Taken together these data 
support a pathogenic role for IL22- induced colonic epithelial ER 
stress in chronic colitis. IL22 significantly amplified ER stress 
induced by tunicamycin, and just as Atg16l1 deficiency promotes 
IL22 induced ER stress in the small intestine, it is likely that 
genetic and/or environmental variables in TRUC disease may 
potentiate IL22- induced ER stress and pathology. IL17A, which 
synergises with IL22 to induce colonic epithelial ER stress, is 
highly produced in the colon of TRUC mice and is function-
ally important in disease.19 20 TRUC disease is characterised by 
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intestinal dysbiosis, including expansion of proinflammatory 
bacteria, such as Helicobacter typhlonius. Intriguingly, related 
Helicobacter species, including Helicobacter hepaticus, have 
been shown to induce ER stress in intestinal epithelial cells.41 42
The molecular mechanisms of IL22 and IL17A engagement 
with the UPR in colonic epithelial cells has not been formally 
tested in this study, although a number of possibilities exist. IL22 
canonically signals through STAT3,43 and in the small intestine, 
IL22- mediated induction of the UPR is STAT3 dependent,11 
indicating that ER stress programme could be directly transcrip-
tionally regulated through STAT3 activation. IL22 also signals 
through MAP kinase pathways, such as MAP3K8,44 which might 
represent a more plausible mechanism of convergence with 
IL17A signalling. Our transcriptomic data hinted at alternative 
mechanisms. IL22 induced Nos2 (inducible nitric oxide synthe-
tase), which as well as mediating DNA damage and colonic 
epithelial carcinogenesis,23 is both a trigger and downstream 
effector of the ER stress response.24 IL22 also upregulated Tlr4 
and its signalling adapter Myd88 in colonoids, and engagement 
of this microbial recognition pathway also induces ER stress 
in colonic epithelial stem cells.45 Therefore, it is possible that 
IL22- induced regulation of TLR4 signalling could sensitise to 
ER stress induction, which might be especially pertinent in vivo 
in the setting of disease processes that microbial dependent, such 
as IBD. Future work will investigate the functional importance 
of these possible mechanisms of engagement.
A major strength of this study is our analysis of colonic 
transcriptomic data from large cohorts of patients with active 
colitis, including colonic CD patients treated with ustekinumab 
or placebo in the context of a large phase III clinical trial. In 
different patient cohorts, the IL22- induced transcriptional 
module was highly enriched in the colon of patients with active 
colonic CD and UC, correlating with disease biomarkers and 
endoscopic severity of disease. Moreover, the expression of IL22 
responsive transcripts strongly correlated with the ER stress 
response transcriptional module in the colon of patients with 
active CD.
In conclusion, data presented in this study advance our under-
standing of IL22 biology in the colon and cast new light on 
pathogenic mechanisms of this important cytokine in chronic 
colitis. The IL22/ER stress axis may be especially important in 
chronic inflammation, where other proinflammatory/proapop-
totic mediators, such as IL17A and TNFα, are also excessively 
and persistently produced. Therapeutic strategies targeting ER 
stress or neutralising effector cytokines responsible for driving 
pathological ER stress responses in the colon are conceptually 
attractive therapeutic approaches for IBD patients with active 
colitis. Likewise, blockade of upstream cytokines, such as IL23, 
may be especially effective in patients with pronounced epithe-
lial ER stress. The role of IL22 in IBD may need reinterpreta-
tion and the rationale for exogenous IL22 supplementation in 
patients with active colitis may need re- evaluation.
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